Entrada Therapeutics (TRDA) Operating Expenses (2020 - 2026)

Entrada Therapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $43.2 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 1.96% year-over-year to $43.2 million; the TTM figure through Mar 2026 stood at $184.1 million (up 9.54% YoY), while the FY2025 annual figure was $183.3 million, up 11.94% from the prior year.
• Operating Expenses was $43.2 million for Q1 2026 at Entrada Therapeutics, down from $43.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $48.8 million in Q2 2025 to a low of $22.2 million in Q1 2022.
• Historically, Operating Expenses has averaged $36.5 million across 5 years, with a median of $38.0 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses surged 163.92% in 2022, then increased 0.56% in 2025.
• A 5-year view of Operating Expenses shows it stood at $25.6 million in 2022, then jumped by 44.43% to $36.9 million in 2023, then advanced by 17.11% to $43.3 million in 2024, then grew by 0.56% to $43.5 million in 2025, then declined by 0.76% to $43.2 million in 2026.
• The last three Operating Expenses figures came in at $43.2 million (Q1 2026), $43.5 million (Q4 2025), and $48.7 million (Q3 2025), per Business Quant data.